Strategic Development of a Native Extracellular Vesicle Platform Technology for Regenerative Medicine Therapeutic Applications
Time: 1:30 pm
day: Conference Day Two
Details:
- EV Therapeutics has broadened our portfolio to include a novel, native EV technology, synergistic with our modified EV therapeutic platform
- This platform technology has strong MOA data and is supported by positive clinical use data outside the USA
- Prioritizing this native EV technology enables EV Therapeutics to chart a more rapid path towards clinical trials and US regulatory approval
NEW DATA!
